IMMP Key Statistics, Chart & Performance
The current stock price of IMMP is 1.84 USD. In the past month the price increased by 0.55%. In the past year, price decreased by -11.96%.
IMMP Latest News, Press Relases and Analysis
IMMP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About IMMP
Company Profile
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Company Info
IMMUTEP LTD-SP ADR
Level 32, Suite 32.07 Australia Square, 264 George Street
Sydney NEW SOUTH WALES 2000 AU
CEO: Marc Voigt
Employees: 0
Phone: 61283157003
IMMUTEP LTD-SP ADR / IMMP FAQ
What does IMMUTEP LTD-SP ADR do?
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
What is the current price of IMMP stock?
The current stock price of IMMP is 1.84 USD. The price decreased by -7.07% in the last trading session.
Does IMMUTEP LTD-SP ADR pay dividends?
IMMP does not pay a dividend.
How is the ChartMill rating for IMMUTEP LTD-SP ADR?
IMMP has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is IMMUTEP LTD-SP ADR (IMMP) stock traded?
IMMP stock is listed on the Nasdaq exchange.
How is the market expecting IMMP stock to perform?
8 analysts have analysed IMMP and the average price target is 2.45 USD. This implies a price increase of 33.25% is expected in the next year compared to the current price of 1.84.
Can you provide the sector and industry classification for IMMUTEP LTD-SP ADR?
IMMUTEP LTD-SP ADR (IMMP) operates in the Health Care sector and the Biotechnology industry.
IMMP Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IMMP. When comparing the yearly performance of all stocks, IMMP turns out to be only a medium performer in the overall market: it outperformed 45.92% of all stocks.
IMMP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMMP. While IMMP seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMMP Financial Highlights
Over the last trailing twelve months IMMP reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS decreased by -14.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.06% | ||
| ROE | -25.43% | ||
| Debt/Equity | 0 |
IMMP Forecast & Estimates
8 analysts have analysed IMMP and the average price target is 2.45 USD. This implies a price increase of 33.25% is expected in the next year compared to the current price of 1.84.
For the next year, analysts expect an EPS growth of -30.56% and a revenue growth -21.33% for IMMP